Hugo Fry

Written by Trophic Communications on 2. May 2024.

Search

Recent Posts

BioCentury Grand Rounds Europe
Topas Therapeutics’ TPM502 Achieves Gluten-specific Tolerance Induction, Positive Safety Profile in Phase 2a Trial in Celiac Disease Patients
Topas Therapeutics Announces Presentation of Phase 2a Data for TPM502 in Celiac Disease at Digestive Disease Week® 2025 in San Diego
Topas Therapeutics Publishes Foundational Data Demonstrating Tolerance Induction by its Proprietary Nanoparticle Platform in Frontiers in Immunology
Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial Evaluating TPM502 in Patients with Celiac Disease